menu
    • menu
    [{"orgOrder":0,"company":"Vector Pharma","sponsor":"R-Pharm","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2021","type":"Licensing Agreement","leadProduct":"Ixabepilone","moa":"Tubulin","graph1":"Oncology","graph2":"Approved","graph3":"Vector Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Intravenous Infusion","sponsorNew":"Vector Pharma \/ R-PHARM","highestDevelopmentStatusID":"12","companyTruncated":"Vector Pharma \/ R-PHARM"},{"orgOrder":0,"company":"Vector Pharma","sponsor":"Ascendis Pharma","pharmaFlowCategory":"D","therapeuticArea":"Endocrinology","country":"","productType":"Large molecule","year":"2024","type":"Agreement","leadProduct":"Lonapegsomatropin","moa":"","graph1":"Endocrinology","graph2":"Approved","graph3":"Vector Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Endocrinology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Vector Pharma \/ Ascendis Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Vector Pharma \/ Ascendis Pharma"},{"orgOrder":0,"company":"Vector Pharma","sponsor":"Oncopeptides","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"Melphalan Flufenamide","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Vector Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vector Pharma \/ Vector Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Vector Pharma \/ Vector Pharma"},{"orgOrder":0,"company":"Vector Pharma","sponsor":"Oncopeptides","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Peptide","year":"2024","type":"Collaboration","leadProduct":"Melphalan Flufenamide","moa":"","graph1":"Oncology","graph2":"Approved","graph3":"Vector Pharma","amount2":0,"highestDevelopmentShortName":"Approved","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Vector Pharma \/ Vector Pharma","highestDevelopmentStatusID":"12","companyTruncated":"Vector Pharma \/ Vector Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Vector Pharma

    Menu

    Vector Pharma

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Vector Pharma

                            U.A.E arrow
                            2024 ACI Convention
                            Not Confirmed

                            Vector Pharma

                            U.A.E arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Melphalan Flufenamide,Dexamethasone

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Recipient : Oncopeptides

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Oncopeptides Partners with Vector to Distribute Pepaxti in MENA for Multiple Myeloma

                            Details : Under the collaboration, Vector will distribute Pepaxti (melphalan flufenamide), indicated in combination with dexamethasone, to patients in the MENA region for patients with multiple myeloma.

                            Brand Name : Pepaxti

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            March 30, 2024

                            Lead Product(s) : Melphalan Flufenamide,Dexamethasone

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Recipient : Oncopeptides

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Vector Pharma

                            U.A.E arrow
                            2024 ACI Convention
                            Not Confirmed

                            Vector Pharma

                            U.A.E arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Melphalan Flufenamide,Dexamethasone

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Recipient : Oncopeptides

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Oncopeptides and Vector Pharma Announce Collaboration to Provide Pepaxti in MENA Region

                            Details : Under the agreement, Vector will distribute Pepaxti (melphalan flufenamide), indicated in combination with dexamethasone, in the MENA region for the treatment of patients with multiple myeloma.

                            Brand Name : Pepaxti

                            Molecule Type : Peptide

                            Upfront Cash : Undisclosed

                            March 27, 2024

                            Lead Product(s) : Melphalan Flufenamide,Dexamethasone

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Recipient : Oncopeptides

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Vector Pharma

                            U.A.E arrow
                            2024 ACI Convention
                            Not Confirmed

                            Vector Pharma

                            U.A.E arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Lonapegsomatropin

                            Therapeutic Area : Endocrinology

                            Study Phase : Approved

                            Sponsor : Ascendis Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Vector Pharma Signs Distribution Agreement for Skytrofa and Yorvipath

                            Details : Vector will distribute Skytrofa (lonapegsomatropin-tcgd) for pediatric growth hormone deficiency and Yorvipath for adult hypoparathyroidism in the GCC countries, using its sales expertise.

                            Brand Name : Skytrofa

                            Molecule Type : Large molecule

                            Upfront Cash : Undisclosed

                            January 08, 2024

                            Lead Product(s) : Lonapegsomatropin

                            Therapeutic Area : Endocrinology

                            Highest Development Status : Approved

                            Sponsor : Ascendis Pharma

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Vector Pharma

                            U.A.E arrow
                            2024 ACI Convention
                            Not Confirmed

                            Vector Pharma

                            U.A.E arrow
                            2024 ACI Convention
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Ixabepilone,Capecitabine

                            Therapeutic Area : Oncology

                            Study Phase : Approved

                            Sponsor : R-Pharm

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Vector Pharma FZCO signs Exclusive License and Distribution Rights to IXEMPRA in the Middle East

                            Details : Under the agreement, R-PHARM US has appointed Vector Pharma as exclusive distributor to import, use, market, sell and distribute Ixempra (ixabepilone) in the Middle East & North African territories.

                            Brand Name : Ixempra

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            December 22, 2021

                            Lead Product(s) : Ixabepilone,Capecitabine

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved

                            Sponsor : R-Pharm

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth